-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor A few days ago, Eli Lilly and Company today announced updated data from a Phase 1/2 clinical trial of the RET inhibitor Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC)
.
Trial results showed that Retevmo brought sustained remission to patients at a median follow-up of about two years
.
Retevmo, a potent RET kinase inhibitor, received its first accelerated approval from the U.
S.
FDA in 2020 for the treatment of three cancers, non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer
.
These patients' tumors had fusions or mutations in the RET gene
.
The newly published clinical trial data included 355 patients eligible for efficacy analysis, 247 of whom had previously received at least first-line platinum-containing chemotherapy and 69 treatment-naïve patients
.
58% of patients received anti-PD-1 or anti-PD-L1 antibody therapy
.
The confirmed objective response rate (ORR) was 61.
1% (95% CI: 54.
7-67.
2%) in patients who had received platinum-based chemotherapy and 84.
1% (95% CI: 54.
7-67.
2%) in 69 treatment-naïve patients : 73.
3-91.
8%)
.
Twenty-six patients had measurable central nervous system (CNS) metastases at baseline, and treatment with Retevmo resulted in a CNS ORR of 84.
6%
.
At a median follow-up of approximately 2 years in treatment-naïve and platinum-chemotherapy-experienced patients, median duration of response (DoR) was 20.
2 months and 28.
6 months, and median progression-free survival (PFS) estimates were 22.
0 and 22.
0 months, respectively.
24.
9 months
.
Among 26 patients with evaluable CNS disease, the median intracranial PFS with Retevmo was 19.
4 months
.
These median estimates are still premature
.
"These results continue to provide evidence that Retevmo is delivering meaningful clinical improvement in patients with metastatic RET fusion-positive NSCLC, including those with difficult-to-treat brain metastases
,
" said Dr.
David Hyman, chief medical officer, Lilly Oncology
.
Reference: [1] Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress.
Retrieved April 1, 2022, from https:/ /investor.
lilly.
com/news-releases/news-release-details/lilly-presents-updated-data-retevmor-selpercatinib-advanced-ret.
Retrieved April 1, 2022, from https:// news/home/20220401005519/enDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
Trial results showed that Retevmo brought sustained remission to patients at a median follow-up of about two years
.
Retevmo, a potent RET kinase inhibitor, received its first accelerated approval from the U.
S.
FDA in 2020 for the treatment of three cancers, non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer
.
These patients' tumors had fusions or mutations in the RET gene
.
The newly published clinical trial data included 355 patients eligible for efficacy analysis, 247 of whom had previously received at least first-line platinum-containing chemotherapy and 69 treatment-naïve patients
.
58% of patients received anti-PD-1 or anti-PD-L1 antibody therapy
.
The confirmed objective response rate (ORR) was 61.
1% (95% CI: 54.
7-67.
2%) in patients who had received platinum-based chemotherapy and 84.
1% (95% CI: 54.
7-67.
2%) in 69 treatment-naïve patients : 73.
3-91.
8%)
.
Twenty-six patients had measurable central nervous system (CNS) metastases at baseline, and treatment with Retevmo resulted in a CNS ORR of 84.
6%
.
At a median follow-up of approximately 2 years in treatment-naïve and platinum-chemotherapy-experienced patients, median duration of response (DoR) was 20.
2 months and 28.
6 months, and median progression-free survival (PFS) estimates were 22.
0 and 22.
0 months, respectively.
24.
9 months
.
Among 26 patients with evaluable CNS disease, the median intracranial PFS with Retevmo was 19.
4 months
.
These median estimates are still premature
.
"These results continue to provide evidence that Retevmo is delivering meaningful clinical improvement in patients with metastatic RET fusion-positive NSCLC, including those with difficult-to-treat brain metastases
,
" said Dr.
David Hyman, chief medical officer, Lilly Oncology
.
Reference: [1] Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress.
Retrieved April 1, 2022, from https:/ /investor.
lilly.
com/news-releases/news-release-details/lilly-presents-updated-data-retevmor-selpercatinib-advanced-ret.
Retrieved April 1, 2022, from https:// news/home/20220401005519/enDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
